Claudia Mara Ribeiro1, Sayonara Rangel Oliveira1,2, Daniela Frizon Alfieri1, Tamires Flauzino1, Damacio Ramón Kaimen-Maciel3, Andréa Name Colado Simão1,2, Michael Maes4,5, Edna Maria Vissoci Reiche6,7. 1. Laboratory of Applied Immunology, Health Sciences Center, University of Londrina, Paraná, Brazil. 2. Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil. 3. Hospital Santa Casa de Misericórdia de Londrina, Londrina, Brazil. 4. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia. 5. Department of Psychiatry, King Chulalongkorn Memorial Hospital, Chulalongkorn, Bangkok, Thailand. 6. Laboratory of Applied Immunology, Health Sciences Center, University of Londrina, Paraná, Brazil. reiche@sercomtel.com.br. 7. Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil. reiche@sercomtel.com.br.
Abstract
BACKGROUND: The association between tumor necrosis factor (TNF)-α, soluble TNF receptor (sTNFR)1 and sTNFR2 with clinical characteristics of multiple sclerosis (MS) remains unclear. OBJECTIVE: To examine whether TNF-α, sTNFR1 and sTNFR2 are associated with MS diagnosis, disability, disability progression and clinical forms of MS. MATERIALS AND SUBJECTS: The study included 147 patients with relapsing-remitting MS (RRMS), 21 with progressive clinical forms (ProgMS) and 70 controls. Expanded Disability Status Scale (EDSS) evaluated disability as mild (EDSS < 3.0) or moderate/high (EDSS ≥ 3.0). Multiple Sclerosis Severity Score (MSSS) evaluated disability progression as no progression (MSSS < 5) and progression (MSSS ≥ 5). Baseline data of subjects and plasma levels of TNF-α, sTNFR1, sTNFR2 were obtained. RESULTS: The MS diagnosis explained 44.6% and 12.3% of TNF-α and sTNFR2 levels, respectively. Moderate/high disability and disability progression were best predicted by sTNFR1 and age (positively) and ProgMS were best predicted by sTNFR1 (positively) and sTNFR2 (negatively), coupled with age and sex. A composite score reflecting the sTNFR1/sTNFR2 ratio showed a positive association with ProgMS after adjusting for age and sex. CONCLUSION: Increased sTNFR1 and age were positively associated with disability and disability progression, whereas increased sTNFR1 (positively) and sTNFR2 (negatively) were associated with ProgMS, suggesting a distinct role of them in the immunopathological mechanisms of MS.
BACKGROUND: The association between tumor necrosis factor (TNF)-α, soluble TNF receptor (sTNFR)1 and sTNFR2 with clinical characteristics of multiple sclerosis (MS) remains unclear. OBJECTIVE: To examine whether TNF-α, sTNFR1 and sTNFR2 are associated with MS diagnosis, disability, disability progression and clinical forms of MS. MATERIALS AND SUBJECTS: The study included 147 patients with relapsing-remitting MS (RRMS), 21 with progressive clinical forms (ProgMS) and 70 controls. Expanded Disability Status Scale (EDSS) evaluated disability as mild (EDSS < 3.0) or moderate/high (EDSS ≥ 3.0). Multiple Sclerosis Severity Score (MSSS) evaluated disability progression as no progression (MSSS < 5) and progression (MSSS ≥ 5). Baseline data of subjects and plasma levels of TNF-α, sTNFR1, sTNFR2 were obtained. RESULTS: The MS diagnosis explained 44.6% and 12.3% of TNF-α and sTNFR2 levels, respectively. Moderate/high disability and disability progression were best predicted by sTNFR1 and age (positively) and ProgMS were best predicted by sTNFR1 (positively) and sTNFR2 (negatively), coupled with age and sex. A composite score reflecting the sTNFR1/sTNFR2 ratio showed a positive association with ProgMS after adjusting for age and sex. CONCLUSION: Increased sTNFR1 and age were positively associated with disability and disability progression, whereas increased sTNFR1 (positively) and sTNFR2 (negatively) were associated with ProgMS, suggesting a distinct role of them in the immunopathological mechanisms of MS.
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: Tanja Spoettl; Martin Hausmann; Frank Klebl; Andrea Dirmeier; Bodo Klump; Joerg Hoffmann; Hans Herfarth; Antje Timmer; Gerhard Rogler Journal: Inflamm Bowel Dis Date: 2007-06 Impact factor: 5.325
Authors: Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Sueli Donizete Borelli; Damácio Ramon Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche Journal: J Neurol Sci Date: 2014-08-20 Impact factor: 3.181
Authors: M Grell; E Douni; H Wajant; M Löhden; M Clauss; B Maxeiner; S Georgopoulos; W Lesslauer; G Kollias; K Pfizenmaier; P Scheurich Journal: Cell Date: 1995-12-01 Impact factor: 41.582
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Adam P Gregory; Calliope A Dendrou; Kathrine E Attfield; Aiden Haghikia; Dionysia K Xifara; Falk Butter; Gereon Poschmann; Gurman Kaur; Lydia Lambert; Oliver A Leach; Simone Prömel; Divya Punwani; James H Felce; Simon J Davis; Ralf Gold; Finn C Nielsen; Richard M Siegel; Matthias Mann; John I Bell; Gil McVean; Lars Fugger Journal: Nature Date: 2012-08-23 Impact factor: 49.962
Authors: Jianya Peng; Chandler B Sy; John J Ponessa; Alexander D Lemenze; Christina M Hernandez; Juan M Inclan-Rico; Arman Sawhney; Hannah G Federman; Krupa Chavan; Vanessa Espinosa; Sergei V Kotenko; Amariliz Rivera; Mark C Siracusa Journal: Proc Natl Acad Sci U S A Date: 2022-09-07 Impact factor: 12.779
Authors: Carmen Picon; Anusha Jayaraman; Rachel James; Catriona Beck; Patricia Gallego; Maarten E Witte; Jack van Horssen; Nicholas D Mazarakis; Richard Reynolds Journal: Acta Neuropathol Date: 2021-02-10 Impact factor: 17.088
Authors: A Navarro-Sempere; P Martínez-Peinado; A S Rodrigues; P V Garcia; R Camarinho; M García; Y Segovia Journal: Mediators Inflamm Date: 2021-10-11 Impact factor: 4.711